IP Library › Granted Patent US 8,257,950
Granted Patent B2
US 8,257,950 · App. 13/159,323 · Granted Sep 4, 2012

Bisulfite conversion of DNA

Assignee: Epigenomics AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,257,950
App. No.
13/159,323
Granted
Sep 4, 2012
Kind
B2
Abstract

The present invention provides an improved method for the bisulfite conversion of DNA, and facilitates the analysis of cytosine methylation of genomic DNA. Novel combinations of denaturing solvents, new reaction conditions and new purification methods provide surprisingly efficacious methods for bisulfite conversion of DNA relative to prior art methods. The converted DNA may subsequently be analyzed by many different methods.

Claims (7)

1. A method for bisulfite conversion of DNA, comprising reacting isolated genomic DNA with a bisulfite reagent, wherein the reaction is conducted at a temperature in the range of 0-80° C., and wherein the reaction temperature is increased at least once to a range of about 85-100° C. for a duration of between about 15 seconds and 6 minutes during the course of the conversion.

2. The method according to claim 1 , wherein the temperature is increased from 2 to 5 times.

3. The method according to claim 1 , wherein the reaction temperature is increased to about 90 to 98° C.

4. The method according to claim 1 , wherein the converted DNA is purified via magnetic particles.

5. The method according to claim 1 , wherein the DNA is from tissue samples or bodily fluids.

6. A method for at least one of diagnosis and prognosis of an adverse event for patients or individuals, comprising use of a method according to claim 1 , wherein the adverse event is at least one event selected from the category group consisting of: undesired drug interactions; cancer diseases; CNS malfunctions, damage or disease; symptoms of aggression or behavioral disturbances; clinical, psychological and social consequences of brain damage; psychotic disturbances and personality disorders; dementia; cardiovascular disease, malfunction and damage; malfunction, damage or disease of the gastrointestinal tract; malfunction, damage or disease of the respiratory system; lesion, inflammation, infection, immunity and/or convalescence; malfunction, damage or disease of the body as an abnormality in the development process; malfunction, damage or disease of the skin, of the muscles, of the connective tissue or of the bones; endocrine and metabolic malfunction, damage or disease; headaches or sexual malfunction.

7. A method for distinguishing cell types or tissues, or for investigating cell differentiation, comprising use of a method according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2018
From: EPIGENOMICS AG
To: QIAGEN GMBH
Reel/Frame 045995/0514 →
Continuity (4)
Division 12410389 · Mar 24, 2009
Continuation 10964167 · Oct 12, 2004
Continuation In Part 10311661
Related Publication 20110250601A1 · Oct 13, 2011